BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent ...

In a challenging year for Aclarion, the medical technology company's stock has plummeted to a 52-week low, trading at $4.41. According to InvestingPro data, the company maintains a healthy liquidity ...

The trial aims to validate Nociscan’s ability to improve surgical outcomes for chronic low back pain patients. Enrolling 300 patients across multiple sites, it builds on peer-reviewed data ...

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in ...

Aclarion, Inc. has announced that Northwestern Medicine will serve as the initial site for its pivotal clinical trial, CLARITY, designed to assess the effectiveness and economic value of Nociscan ...

Northwestern Medicine is a global leader in clinical trial research, including spineCLARITY is a randomized study designed to demonstrate ...

Aclarion stock is trading higher on Tuesday after the company announced it secured funding for its CLARITY trial of its ...

Aclarion, Inc. is set to showcase its advanced platform, NOCISCAN, at the Selby Spine Conference, presented by Dr. Sigurd Berven. NOCISCAN combines MR Spectroscopy and augmented intelligence to ...

Aclarion, Inc. (NASDAQ: ACON) shares cleared breakeven Tuesday, as the health-care technology company announced it has received a Notice of Allowance from the United States Patent and Trademark Office ...

Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE ...

Renowned spine specialist, Dr. Sigurd Berven, will present Aclarion's flagship platform, NOCISCAN, highlighting its innovative, evidence-supported capabilities. “Aclarion is pleased to have ...